Zhao said China expects its vaccines, after completion of research and development, will be included on the purchasing list of the COVAX initiative at an early date, to make its contributions to vaccine accessibility and affordability in developing countries.
The phase 2 trial saw 560 participants, 240 of whom were over 70, split into groups that received either one or two doses of the vaccine, or a placebo.
Speaking at an event on "Shifting Healthcare Paradigm During and Post-Covid", the Health Minister stressed the importance of following safety protocols, and said that vaccine distribution will be rolled out with a scientific and systematic approach. These results are also consistent with the Phase I data that showed immunity in the adults from ages 18 to 55.
"We were pleased to see that our vaccine was not only well tolerated in older adults, but also stimulated similar immune responses to those seen in younger volunteers".More news: Denmark says mutated coronavirus from mink farms 'most likely' extinct
"The next step will be to see if this translates into protection from the disease itself". Oxford is developing its vaccine in conjunction with the drugmaker AstraZeneca.
"But we're not thinking that we're going to need to boost people more often than once a year as we do with a flu vaccine".
Because only a Phase 3 trial includes enough people - and runs for long enough for the volunteers included to actually catch Covid - and therefore prove whether your vaccine works or not.
This is a very encouraging result.
Speaking about when results indicating whether the vaccine works will be published, Prof Pollard said he is hopeful it will be before the end of the year.More news: AstraZeneca COVID-19 vaccine shows promise in elderly, trial results by Christmas
When data from this stage is sent to the regulators, scrutinised and approved, the vaccine can be given the green light to be used on people worldwide.
"We're on the cusp of being able to protect those elderly people, who we love, through vaccination", he told Radio 4's Today programme.
Researchers say their findings are promising as they show that older people are showing a similar immune response to younger adults. Adding that, "We hope that this means our vaccine will help to protect some of the most vulnerable people in society, but further research will be needed before we can be sure".
Three vaccines - Pfizer-BioNTech, Sputnik and Moderna - have already reported good preliminary data from phase three trials, with one suggesting 94% of over-65s could be protected from Covid-19.
And given the United Kingdom has bet most heavily on the Oxford vaccine in terms of investment and numbers of doses ordered, a positive result will be the Christmas present we've all been waiting for.More news: Jesy Nelson Announces Extended Time Off From Little Mix
Pharmaceutical firms Pfizer and Moderna announced that their vaccine candidates have shown success in late-stage trials, prompting a range of reactions on social media. Tracking and tracing of the vaccine would be neck-deep once it's available for the public.